1. Scrip
  2. >>Business

Novo Preempts Earnings Reveal With Preview Of Wegovy-Driven Growth

Blockbuster Obesity Treatment To Face New Rival This Year

 
• By Mandy Jackson

Novo Nordisk said sales increased 25% in the first quarter, driven by US demand for GLP-1 agonist Wegovy for obesity, and increased its 2023 sales growth guidance from a range of 13%-19% to 24%-30%.

Syringe with a needle and yellow measuring tape. Injections for body beauty and weight loss.
Novo projects significant growth from its weight loss leader Wegovy • Source: Shutterstock

Excitement about the sales potential of GLP-1 agonists for the treatment of obesity is so strong that Novo Nordisk A/S is boasting about the performance of its top-seller in the class, Wegovy (semaglutide), nearly three weeks ahead of its first quarter earnings report scheduled for 4 May. The Danish big pharma announced on 13 April that its total product sales increased 25% in Q1 versus the same period in 2022, largely due to increased US demand for Wegovy, and it now is projecting 24%-30% companywide sales growth for the year, up from prior guidance of 13%-19%.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Gilead Set To Expand Trodelvy/Keytruda Into Frontline TNBC

 
• By Alaric DeArment

The company reported positive topline results for ASCENT-04, which also bode well for the ASCENT-03 trial in patients with low PD-L1 expression.

Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Eleanor Malone

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Enhertu Takes The First-Line Throne In HER2 Metastatic Breast Cancer

 
• By Jessica Merrill

AstraZeneca and Daiichi’s DESTINY-Breast09 trial testing Enhertu with pertuzumab versus standard of care showed a statistically significant and meaningful PFS improvement.